Gene therapy of hypertensive vascular injury

被引：2

作者：

Chu Y. ^{[1
]}

Faraci F.M. ^{[2
]}

Heistad D.D. ^{[3
]}

机构：

[1] Cardiovascular Center, Department of Internal Medicine, University of Iowa, Iowa City

[2] Cardiovascular Center, Department of Internal Medicine and Pharmacology, University of Iowa College of Medicine, Iowa City

[3] Cardiovascular Center, Department of Internal Medicine and Pharmacology, University of Iowa, Iowa City

来源：

Current Hypertension Reports | 2000年 / 2卷 / 1期

关键词：

Gene Therapy; Gene Transfer; Vascular Injury; Atrial Natriuretic Peptide; Angiotensinogen;

D O I：

10.1007/s11906-000-0065-4

中图分类号：

学科分类号：

摘要：

Hypertension and vascular injury usually require prolonged treatment, and compliance is a key to efficacy for pharmacologically-based antihypertensive therapy. Gene therapy has the potential to be long lasting, with few side effects. Recent studies have provided promising results, in which hypertension can be treated by either augmentation of vasodilation or inhibition of vasocon-striction through gene transfer in experimental models. Gene transfer is also becoming useful for the study of mechanisms of physiologic and pathophysiologic conditions, including hypertension. In this mini-review, we summarize some recent studies in this area of research, and suggest some areas where progress is needed t advance the research toward gene therapy. Copyright © 2000 by Current Science Inc.

引用

页码：92 / 97

页数：5

共 50 条

[1] Heistad D.D., Faraci F.M., Gene therapy for cerebral vascular disease, Stroke, 27, pp. 1688-1693, (1996)
[2] Phillips M.I., Is gene therapy for hypertension possible?, Hypertension, 33, pp. 8-13, (1999)
[3] Daniels V., Casey A., Antihypertensives, Phys Med Rehabil Clin North Am, 10, pp. 319-335, (1999)
[4] De Gasparo M., Levens N., Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme?, Pharmacol Toxicol, 82, pp. 257-271, (1998)
[5] Dzau V.J., Gibbons G.H., Morishita R., Pratt R.E., New perspectives in hypertension research, potentials of vascular biology, Hypertension, 23, pp. 1132-1140, (1994)
[6] Lifton R.P., Molecular genetics of human blood pressure variation, Science, 272, pp. 676-680, (1996)
[7] Zabner J., Ramsey B.W., Meeker D.P., Et al., Repeat administration of an adenovirus vector encoding cystic fibrosis transmem-brane conductance regulator to the nasal epithelium of patients with cystic fibrosis, J Clin Invest, 97, pp. 1504-1511, (1996)
[8] Allikmets K., Parik T., Viigimaa M., The renin-angiotensin system in essential hypertension: Associations with cardiovascular risk, Blood Press, 8, pp. 70-78, (1999)
[9] Schiffrin E.L., Role of endothelin-1 in hypertension, Hypertension, 34, pp. 876-881, (1999)
[10] Margolius H.S., Kallikreins, kinins and cardiovascular diseases: A short review, Biol Res, 31, pp. 135-141, (1998)

← 1 2 3 4 5 →